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Table 1 Baseline characteristics of IgAN patients.
Variables Blood group P value
B antigen group (n Z 366) non-B antigen group (n Z 553)
AB (n Z 93) B (n Z 273) p value A (n Z 252) O (n Z 301) p value
Follow-up (months) 52.43  37.92 59.57  41.24 0.14 58.06  41.78 56.6  40.67 0.68 0.51
Age at biopsy (years) 35.3  11.97 36.76  11.9 0.31 37.08  13.37 37.1  11.74 0.99 0.64
Gender (Male: Female) 0.58 (34:59) 0.81 (122:151) 0.17 1.25 (140:112) 1.05 (154:147) 0.30 0.005*
Body mass index (kg/m2) 22.72  3.47 22.73  3.22 0.99 23.24  3.41 23.26  3.43 0.95 0.20
Serum creatinine (mg/dl) 0.96 (0.49e4.06) 1.05 (0.44e4.24) 0.65 1.13 (0.49e4.12) 1.2 (0.35e5.18) 0.37 <0.001*
eGFR (mL/mm/1.73 m2) 83.55  37.69 80.51  33.63 0.49 73.67  33.24 71.46  34.25 0.44 0.001*
CKD stage 1 (%) 45 (48.4%) 113 (41.4%) 0.06 88 (34.9%) 91 (30.2%) 0.27 0.006*
CKD stage 2 (%) 13 (14.0%) 74 (27.1%) 66 (26.2%) 84 (27.9%)
CKD stage 3 (%) 29 (31.2%) 65 (23.8%) 77 (30.6%) 87 (28.9%)
CKD stage 4 (%) 6 (6.5%) 21 (7.7%) 21 (8.3%) 39 (13.0%)
SBP (mm Hg) 125.04  16.77 125.33  16.55 0.88 129.5  18.68 128.16  17.09 0.38 0.02*
DBP (mm Hg) 78.16  12.57 80  11.39 0.19 81.41  12.48 82.15  12.57 0.49 0.02*
MAP (mm Hg) 93.79  13.32 95.11  12.26 0.38 97.44  13.55 97.48  13.19 0.97 0.02*
Hypertension (%) 22/93 (23.7%) 82/273 (30%) 0.24 100/252 (39.7%) 121/301 (40.2%) 0.90 0.003*
Blood urea nitrogen (mg/dL) 14.29 (7.28e53.5) 15.13 (6.44e54.06) 0.32 16.95 (5.88e120.45) 17.65 (5.88e76.47) 0.14 0.001*
Serum uric add (mg/dL) 6.09  1.61 6.22  1.73 0.51 6.58  1.86 6.48  1.73 0.49 0.03*
Hyperuricemia (%) 30/93 (32.3%) 102/272 (37.5%) 0.36 98/252 (38.9%) 123/300 (41.0%) 0.61 0.48
Serum total protein (g/dL) 6.19  0.88 6.28  0.88 0.42 6.29  0.91 6.26  0.89 0.66 0.82
Serum albumin (g/dL) 3.5 (1.8e5) 3.6 (0.9e5) 0.12 3.6 (0.7e4.9) 3.6 (1e4.9) 0.72 0.45
Hypoalbuminemia (%) 19/93 (20.4%) 48/272 (17.6%) 0.55 41/252 (16.3%) 44/300 (14.7%) 0.60 0.57
Serum triglycerides (mg/dL) 147.03 (39.86e654.56) 159.43 (42.52e1140.83) 0.19 176.26 (40.74e752.88) 147.48 (50.49e1034.54) 0.05* 0.14
Serum cholesterol (mg/dL) 190.64 (100.15e474.48) 193.74 (32.1e512.76) 0.75 196.25 (59.55e576.57) 192.38 (32.1e696.83) 0.67 0.93
Hemoglobin (g/dl) 12.83  1.71 13.15  1.91 0.15 12.84  1.98 12.8  2.11 0.83 0.14
Anemia (%) 38/93 (40.9%) 98/272 (36.0%) 0.41 110/252 (43.7%) 130/300 (43.3%) 0.94 0.24
Plt (103/mm3) 214.86  60.73 218.92  63.24 0.59 216.73  61.55 215.29  64.58 0.79 0.91
WBC (103/mm3) 7.11 (4.3e19) 7.1 (3.5e17.7) 0.54 7.3 (3.7e20.1) 7.1 (3.2e22.8) 0.78 0.84
Serum IgA (mg/dL) 317.5 (70.3e688) 325 (112e706) 0.56 320.5 (99e930) 322.5 (68e781) 0.81 0.93
Serum IgM (mg/dL) 118 (30e400) 126.5 (25e714) 0.90 116.5 (29e408) 126 (14e479) 0.17 0.36
Serum IgG (mg/dL) 1123.95  445.46 1105.83  358.08 0.70 1110.19  331.67 1128.1  346.69 0.55 0.89
Serum C3 (mg/dL) 102 (61.9e198) 104 (42.7e204) 0.64 101 (62e218) 100 (55e181) 0.29 0.23
Serum C4 (mg/dL) 22.1 (12e56) 24.45 (10.25e63) 0.11 23.4 (10.6e75.7) 23.7 (8e80) 0.58 0.42
Urine protein excretion (g/24 h) 1.08 (0.03e8.53) 1.02 (0.04e12.7) 0.69 1.18 (0.02e10.1) 1.2 (0.05e13.91) 0.32 0.26
ESRD (%) 3/93 (3.2%) 23/273 (8.4%) 0.09 42/252 (16.7%) 56/301 (18.6%) 0.55 <0.001*
ACEI or ARB treatment (%) 73/93 (78.5%) 235/273 (86.1%) 0.08 213/252 (84.5%) 258/301 (85.7%) 0.70 0.33
Glucocorticoid treatment (%) 61/93 (65.6%) 150/273 (54.9%) 0.07 143/252 (56.7%) 166/301 (55.1%) 0.71 0.31
Data are presented as n (%) or mean  SD or median and interquartile range. eGFR: estimated glomerular filtration rate; SBP: systolic blood pressure; DBP:
diastolic blood pressure; MAP: mean arterial pressure; PLT: platelet count; WBC: white blood cell count; Ig: immunoglobulin; C: complement; ACEI: angio-
tensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; *p < 0.05.
S44 IgA NephropathyFigure 1. Kaplan-Meier outcome-free survival curves. Patients from B an-
tigen group (black) versus non-B antigen group (red).http://dx.doi.org/10.1016/j.hkjn.2015.08.1250373
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Background: A large number of crescent formation (> 50% of all glomeruli)
often lead to rapidly progressive renal failure in patients with IgA nephrop-
athy (IgAN). However, little is known of clinical outcomes of moderate cres-
cent formation (10e50% of all glomeruli) in IgAN. The aim of this study is to
investigate clinical characteristics and outcomes of IgAN patients with mod-
erate crescent formation.
Methods: Primary biopsy-proven IgAN patients from two extend renal centers
in Shanghai and Beijingwere enrolled. Patients secondary to systemic diseases
or followed up less than 12 months were excluded. Patients were classified to
mild (1e10%) or moderate (11e50%) crescent group based on the percentage
of glomeruli with crescents. Baseline data were collected at the time of renal
biopsy and during follow-up, including gender, age, mean arterial pressure
(MAP), proteinuria, serum creatinine, histological parameters and therapy.
Results: A total of 1145 patients were recruited. There were 265 and 254 pa-
tients in mild and moderate crescent group respectively. Compared to pa-
tients without crescent formation, patients in mild or moderate crescent
IgA Nephropathy S45group were younger and had more proteinuria. Histologically, patients with
crescent formation had more serious mesangial hypercellularity, endocapil-
lary hypercellularity and segmental glomerulosclerosis. ESRD occurred in 113
individuals during a median follow-up time of 34 months, of whom 18 (6.8%)
were in mild crescent group and 33 (13.0%) were in moderate crescent
group. Mild (HR 0.70, 95% CI 0.35e1.42, PZ 0.32) or moderate crescent for-
mation (HR 0.89, 95% CI 0.52e1.53, PZ 0.68) were not independently asso-
ciated with ESRD by Cox regression proportional hazards models after
adjusted by serum creatinine (HR 2.47, 95% CI 1.89e3.21, P < 0.001), MAP
(HR 1.02, 95% CI 1.004e1.03, P Z 0.013), mesangial hypercellularity (HR1.90, 95% CI 1.15e3.14, P Z 0.01), severe segmental glomerulosclerosis
(HR 2.29, 95% CI 1.15e4.55, P Z 0.018) and tubular atrophy and interstitial
fibrosis (HR 7.48, 95% CI 3.47e12.12, P < 0.001).
Conclusion: IgAN with crescent formation has distinct clinical and patholog-
ical characteristics. Moderate crescent formation is not associated with an
increased risk of poor renal outcome.http://dx.doi.org/10.1016/j.hkjn.2015.08.126
